| T cells genetically modified to express an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma JN Brudno, I Maric, SD Hartman, JJ Rose, M Wang, N Lam, ... Journal of Clinical Oncology 36 (22), 2267, 2018 | 819 | 2018 |
| Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma JN Brudno, N Lam, D Vanasse, Y Shen, JJ Rose, J Rossi, A Xue, A Bot, ... Nature medicine 26 (2), 270-280, 2020 | 280 | 2020 |
| CAR T cell therapies for patients with multiple myeloma L Mikkilineni, JN Kochenderfer Nature reviews Clinical oncology 18 (2), 71-84, 2021 | 254 | 2021 |
| Chimeric antigen receptor T-cell therapies for multiple myeloma L Mikkilineni, JN Kochenderfer Blood, The Journal of the American Society of Hematology 130 (24), 2594-2602, 2017 | 245 | 2017 |
| The Bethesda handbook of clinical oncology J Abraham, JL Gulley Lippincott Williams & Wilkins, 2022 | 165 | 2022 |
| A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with … AS Zimmer, E Nichols, A Cimino-Mathews, C Peer, L Cao, MJ Lee, ... Journal for immunotherapy of cancer 7, 1-8, 2019 | 106 | 2019 |
| MCT1 in invasive ductal carcinoma: monocarboxylate metabolism and aggressive breast cancer JM Johnson, P Cotzia, R Fratamico, L Mikkilineni, J Chen, D Colombo, ... Frontiers in cell and developmental biology 5, 27, 2017 | 71 | 2017 |
| Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment L Mikkilineni, D Whitaker-Menezes, M Domingo-Vidal, J Sprandio, ... Seminars in oncology 44 (3), 218-225, 2017 | 59 | 2017 |
| Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days L Mikkilineni, B Yates, SM Steinberg, SA Shahani, JC Molina, T Palmore, ... Blood Advances 5 (23), 5312-5322, 2021 | 47 | 2021 |
| T cells expressing an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor with a fully-human heavy-chain-only antigen recognition domain induce remissions in … L Mikkilineni, EE Manasanch, N Lam, D Vanasse, JN Brudno, I Maric, ... Blood 134, 3230, 2019 | 36 | 2019 |
| The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes AJ Faruqi, JA Ligon, P Borgman, SM Steinberg, T Foley, L Little, ... Blood Advances 6 (23), 6040-6050, 2022 | 33 | 2022 |
| Deep and durable remissions of relapsed multiple myeloma on a first-in-humans clinical trial of T cells expressing an anti-B-cell maturation antigen (BCMA) chimeric antigen … L Mikkilineni, EE Manasanch, D Vanasse, JN Brudno, J Mann, R Sherry, ... Blood 136, 50-51, 2020 | 18 | 2020 |
| Treatment of patients with T cells expressing a fully-human anti-BCMA CAR with a heavy-chain antigen-recognition domain Caused high rates of sustained complete responses and … L Mikkilineni, EE Manasanch, D Natrakul, JN Brudno, J Mann, SL Goff, ... Blood 138, 3837, 2021 | 11 | 2021 |
| Low levels of neurologic toxicity with retained anti-lymphoma activity in a phase I clinical trial of T cells expressing a novel anti-CD19 CAR J Brudno, S Hartman, N Lam, DF Stroncek, JM Rossi, Y Shen, A Xue, ... Blood 132, 697, 2018 | 11 | 2018 |
| Infectious complications associated with CAR T-cell therapy L Mikkilineni, S Shahani, B Yates, SM Steinberg, T Palmore, ... Blood 134, 4449, 2019 | 10 | 2019 |
| Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial JN Brudno, DA Natrakul, J Karrs, N Patel, R Maass-Moreno, MA Ahlman, ... Blood Advances 8 (3), 802-814, 2024 | 9 | 2024 |
| Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain L Mikkilineni, DA Natrakul, N Lam, EE Manasanch, J Mann, KA Weissler, ... Molecular Therapy 32 (2), 503-526, 2024 | 9 | 2024 |
| Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions. JN Brudno, SD Hartman, S Pittaluga, D Stroncek, N Lam, JA Kanakry, ... Journal of Clinical Oncology 36 (15_suppl), 3052-3052, 2018 | 8 | 2018 |
| T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma L Mikkilineni, EE Manasanch, D Natrakul, K Weissler, JN Brudno, J Mann, ... Blood 140 (Supplement 1), 7433-7434, 2022 | 7 | 2022 |
| Integrating Immune Therapies for the Treatment of Multiple Myeloma L Mikkilineni, S Sidana Journal of the National Comprehensive Cancer Network 21 (12), 1303-1311, 2023 | 5 | 2023 |
